India
Lok Sabha: Cough syrup adulteration: Centre tells Lok Sabha Indian missions abroad holding ‘interactions’ to retain confidence in drug regulatory agencies | India News
[ad_1]
NEW DELHI: Replying to a question on impact of incidents of cough syrup adulteration, the Centre on Thursday told the Lok Sabha that Indian missions abroad have been holding “regular interactions with the concerned authorities to retain their confidence within the drug regulatory agencies”. The question was whether the government has undertaken any survey to assess the impact of incidents of cough syrup adulteration/sub-standard items found in products imported from India in the global market.
Trinamool Congress MP Mala Roy asked the minister of commerce and industry if measures are being taken by the government to restore confidence of importers, also whether action has been taken against the companies responsible for the spurious and below-standard products.
In a written reply to Roy’s query, minister of state for commerce and industry, Anupriya Patel informed the House that in the two recent incidents of alleged cough syrup adulteration/sub-standard items found in products exported to Gambia and Uzbekistan action has been taken.
The minister said, in case of Gambia, a joint investigation was carried out by Central Drugs Standard Control Organisation (CDSCO) and State Drug Controller, Haryana, against Maiden Pharmaceuticals Limited, Sonepat (Haryana), and control samples of the drugs were drawn for test and analysis by Regional Drug Testing Laboratory (RDTL), Chandigarh. Based on violations of Good Manufacturing Practices, Haryana issued an order on October 11, 2022, stopping all the manufacturing activities at the Sonepat unit with immediate effect in public interest.
In the case of Uzbekistan, the CDSCO and state drug controller, Uttar Pradesh, conducted a joint investigation at Marion Biotech, Noida (UP). “The manufacturing license of the firm was suspended by the UP licensing authority on January 9, 2023, as of 30 drug samples tested so far, 24 were declared “not of standard quality”, and again out of which 22 fell under the category of adulterated/spurious,” Patel said.
Following these two cases that seemed to have dented the Indian pharma market, “Indian missions abroad are having regular interactions with the authorities to retain the confidence within the drug regulatory agencies. To build confidence and, also to ensure continuity of the trade, Pharmaceuticals Export Promotion Council of India has led business delegations to African and CIS countries and held one-on-one discussions with drug regulating agencies and pharma trade associations assuring them of the quality of Indian generic products.”
The government further said that Pharmexcil is conducting workshops to sensitise exporters on quality management and international standards, besides their compliances.”
Trinamool Congress MP Mala Roy asked the minister of commerce and industry if measures are being taken by the government to restore confidence of importers, also whether action has been taken against the companies responsible for the spurious and below-standard products.
In a written reply to Roy’s query, minister of state for commerce and industry, Anupriya Patel informed the House that in the two recent incidents of alleged cough syrup adulteration/sub-standard items found in products exported to Gambia and Uzbekistan action has been taken.
The minister said, in case of Gambia, a joint investigation was carried out by Central Drugs Standard Control Organisation (CDSCO) and State Drug Controller, Haryana, against Maiden Pharmaceuticals Limited, Sonepat (Haryana), and control samples of the drugs were drawn for test and analysis by Regional Drug Testing Laboratory (RDTL), Chandigarh. Based on violations of Good Manufacturing Practices, Haryana issued an order on October 11, 2022, stopping all the manufacturing activities at the Sonepat unit with immediate effect in public interest.
In the case of Uzbekistan, the CDSCO and state drug controller, Uttar Pradesh, conducted a joint investigation at Marion Biotech, Noida (UP). “The manufacturing license of the firm was suspended by the UP licensing authority on January 9, 2023, as of 30 drug samples tested so far, 24 were declared “not of standard quality”, and again out of which 22 fell under the category of adulterated/spurious,” Patel said.
Following these two cases that seemed to have dented the Indian pharma market, “Indian missions abroad are having regular interactions with the authorities to retain the confidence within the drug regulatory agencies. To build confidence and, also to ensure continuity of the trade, Pharmaceuticals Export Promotion Council of India has led business delegations to African and CIS countries and held one-on-one discussions with drug regulating agencies and pharma trade associations assuring them of the quality of Indian generic products.”
The government further said that Pharmexcil is conducting workshops to sensitise exporters on quality management and international standards, besides their compliances.”
#Lok #Sabha #Cough #syrup #adulteration #Centre #tells #Lok #Sabha #Indian #missions #holding #interactions #retain #confidence #drug #regulatory #agencies #India #News
